$VICR

Davies Philip D sold $1.1M of VICR

Davies Philip D (Corp. VP-Global Sales & Mktg.) sold 3,073 shares of VICOR CORP (VICR) at an average of $356.97 ($348.84–$366.68, $1.10M total) across 11 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Philip D
Published Jul 6, 2026, 3:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 3:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VICR
Neutral
high confidence
Mentioned
$VICR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VICRNeutralLow
01

Why it matters

The newest fact is the disclosed sale size (~3,073 shares; ~$1.10M) and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific developments are included.

02

Market read

Traders may treat this as routine insider activity with low incremental informational content absent other catalysts.

03

What to watch

The filing does not state tax/option exercise context beyond an open-market sale; without additional filings (e.g., buys, grants, or changes in plan), signal quality is limited.

Relevance 5/10Novelty 4/10Timing: Filed July 6; sale executed July 1 (10b5-1)

Background

The article is an SEC Form 4 insider transaction report for Vicor Corp (VICR).

Company-level read

Ticker impact

$VICRNeutralHigh confidence
Context

SEC Form 4 shows VICR Corp VP-Global Sales & Mktg. Philip D. Davies sold about $1.10M of VICR shares under a 10b5-1 plan on July 1.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be short-lived.

Evidence & confidence

The disclosure is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying fundamental catalyst or guidance change in the text.

Market effects

No sector-level read-through provided; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal de-risking or liquidity needs; traders may still watch for follow-on sales/buybacks.

Key entities

  • VICOR CORP

    Subject of the Form 4 insider transaction disclosure.

  • Philip D. Davies

    Corp. VP-Global Sales & Mktg.; sold shares under a 10b5-1 plan.

Related articles

$VICRMedAI 8/10

Vicor (VICR) Q2 2026 Earnings Call Transcript

Vicor’s Q2 2026 earnings call reported product and royalty revenue of $143.4M, up 26.9% sequentially and 1.6% year over year. Advanced products revenue rose to $94.2M. Net income was $49.8M, GAAP diluted EPS $1.40, and cash was $453.6M. The company guided for nearly 10% Q3 revenue growth and over $600M 2026 revenue, citing capacity increases and licensing assumptions.

$VICRMed

Vicor Corp (VICR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

Vicor Corp said a new license agreement will bring $5 million quarterly payments in year one and $10 million in year two, with $15 million contributing to Q2 revenue and additional revenue recognition expected in Q3 and subsequent quarters. Management also discussed fab capacity expansion to support a $2.5 billion revenue goal and said backlog growth stems mainly from existing customer demand.

$VICRMed

VICOR CORP (VICR): Results of Operations and Financial Condition

VICOR CORP (VICR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115827dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF July 21, 2026 For Immediate Release Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2026 Andover, Mass., July 21, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: